BACKGROUND: [177Lu]Lu-PSMA radioligand therapy targets metastatic castration-resistant prostate cancer by delivering radiation to cells expressing prostate-specific membrane antigen (PSMA). The gene discussed is FOLH1; the disease is prostate cancer.